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Abstract
The discovery of HIV-1 as the cause of AIDS was one of the major scientific achievements during
the last century. Here the events leading to this discovery are reviewed with particular attention
to priority and actual contributions by those involved. Since I would argue that discovering HIV was
dependent on the previous discovery of the first human retrovirus HTLV-I, the history of this
discovery is also re-examined. The first human retroviruses (HTLV-I) was first reported by Robert
C. Gallo and coworkers in 1980 and reconfirmed by Yorio Hinuma and coworkers in 1981. These
discoveries were in turn dependent on the previous discovery by Gallo and coworkers in 1976 of
interleukin 2 or T-cell growth factor as it was called then. HTLV-II was described by Gallo's group
in 1982. A human retrovirus distinct from HTLV-I and HTLV-II in that it was shown to have the
morphology of a lentivirus was in my mind described for the first time by Luc Montagnier in an oral
presentation at Cold Spring Harbor in September of 1983. This virus was isolated from a patient
with lymphadenopathy using the protocol previously described for HTLV by Gallo. The first peer
reviewed paper by Montagnier's group of such a retrovirus, isolated from two siblings of whom one
with AIDS, appeared in Lancet in April of 1984. However, the proof that a new human retrovirus
(HIV-1) was the cause of AIDS was first established in four publications by Gallo's group in the May
4th issue of Science in 1984.
Background
Unfortunately the omission of the American scientist
Robert C. Gallo from the 2008 Nobel Prize in Medicine or
Physiology for the discovery of HIV by many has been
viewed as a final scientific verdict handed down by the
Nobel committee of the Karolinska Institutet on an old
controversy between the Institute Pasteur and NIH and
that previous settlements were for political reasons only.
Also, the decision to omit Gallo has resulted in the resur-
rection of false allegations in the media that Gallo and
coworkers at NIH had rediscovered or even stolen the
French HIV isolate previously sent to them from the Pas-
teur Institute. Thus, it could be interpreted as if the Nobel
committee finally had put right an unjust settlement pre-
viously obtained between the French and American scien-
tific groups. There is no doubt or controversy about the
fact that the French group was first to isolate this new
virus. This is what the Nobel committee chose to award.
Two years ago I had the privilege to painstakingly and
thoroughly go through all the literature related to the dis-
covery of HIV. Since the motivation for the Prize by the
Nobel Committee is very limited and the fact that the
Committee members cannot comment on how they came
to their decision, I think it is important that the medical
community gets the correct historical facts about this
important discovery. Therefore, I have written this article.
I would say that what I present below is a fair and accurate
account on the events and work that led to the discovery
of a new virus as the cause of AIDS. Regarding whom
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should get the credit for the discovery of HIV, this review
should enable the reader to come to his or her own con-
clusion. Mine, however, is different from that of those of
my fellow faculty members that presently make up the
Nobel Committee for the Nobel Prize in Physiology or
Medicine. I will here show that by going through the liter-
ature it is evident that Gallo's group was not only first to
show that HIV is the cause of AIDS but that the French
group had not been able to discover this new virus with-
out the active assistance of, as well as, previous work by
Gallo. It will also be evident that Gallo and his associates
had no reason to "steal" any French isolate. Last year this
journal published another account of the 2008 Nobel
Prize [1].
Paving the way for the discovery of HIV
Isolation of a virus means infection, propagation and
(usually cell free) transmission of an infectious agent in
cultured cells. New viruses, for which there are no suscep-
tible cells in culture, have lately also been detected solely
by molecular techniques, e.g. hepatitis C virus by using a
random-primed complementary DNA library from an
infected patient (Michael Houghton) and subtypes of
human papilloma viruses by using hybridization under
low stringency and subsequent DNA cloning (Harald zur
Hausen).
The difficulty in isolating a new virus is choosing the right
cell culture and detection systems and to obtain speci-
mens containing the virus. With a susceptible cell culture
system and a detection system available, isolation of a
new virus is not only possible but also rather straightfor-
ward. In the case of HIV, before the successful isolation of
the first human retrovirus (human T-cell leukemia virus,
now human T-cell lymphotropic virus type I; HTLV-I) by
Robert C. Gallo [2], neither was at hand.
After the discovery of reverse transcriptase from animal
oncogenic RNA viruses (then called oncorna viruses and
now called retroviruses) a large number of publications
on putative discoveries of retrovirus detections in human
malignancies appeared in the early 1970-ties. However,
they were all either owing to contaminations in the labo-
ratories with animal retroviruses or the mitochondrial
DNA-polymerase γ, the latter when the reports were based
on reverse transcriptase activity alone. DNA-polymerase γ
is a normal cellular DNA polymerase which uses RNA as a
primer but not as a template. Therefore, like reverse tran-
scriptase, the activity of DNA-polymerase γ was sensitive
to a ribonuclease treatment [3-5]. This cellular enzyme
was not known at the time. In 1972 Gallo's group [3]
reported that stimulated normal human lymphocytes
contained a ribonuclease sensitive DNA polymerase dis-
tinct from viral RNA-directed DNA polymerase, an
enzyme that Gallo's group characterized further in a
number of publications. The enzyme prefers Mn2+. Unlike
DNA polymerases α and β, the preferred primer-template
for DNA-polymerase γ is (dT)≅15·(A)n  over
(dT)≅15·(dA)n! This third cellular DNA polymerase was
independently from Gallo discovered by Art Weissbach
and they later named it DNA-polymerase γ[6].
From the numerous and erroneous reports on retroviruses
in various human cancers, the notion of human cancer
viruses became in ill repute and rather than talking of
"human tumor viruses" people in science talked of
"human rumor viruses". In fact, as narrated by Gallo in
one of his reviews[7], when Gallo first submitted their
report on HTLV-I to Journal of Virology it was rejected
right away by the editor Robert Wagner "insisting that
they should cease, and not continue to perpetuate the
controversy, strongly implying that we all know human
retroviruses do not exist".
In his quest to find a human retrovirus in lymphoma/
leukemia Gallo developed sensitive and generalized tech-
niques for the detection of reverse transcriptase to dis-
criminate it from cellular DNA polymerases [8,9].
To isolate T cell lymphotropic viruses one needs to be able
to culture T lymphocytes. Working with conditioned
medium to grow lymphocytes, Gallo together with two of
his post doctorial fellows Doris Morgan, Frank Ruscetti
discovered T cell growth factor (TCGF) later named inter-
leukin 2 (IL-2). Hence, the first report of IL-2/TCGF was
by Robert Gallo was published in 1976 [10]. The first
paper by Kendal A. Smith on IL-2/TCGF did not appear
before 1978[11].
I sincerely doubt that anyone would have been looking
for a retrovirus as the etiological agent for AIDS had
HTLV-I not previously been isolated. I will therefore
shortly recapitulate the history of the discovery of this
virus.
The discovery of the first human retrovirus
Reverse transcriptase activity was detected by Gallo's
group in a T-cell line established (using IL-2) from a
patients diagnosed originally with mycosis fungoides
in1979. To show that this was indeed a new human retro-
virus Gallo and coworkers set out to show that the same
virus could be isolated from primary tissue samples of the
same patient by culturing primary T-cells with IL-2; dem-
onstrate that the virus was novel, i.e., not any of the
known animal retroviruses; show it could infect human T
cells in vitro; demonstrate specific antibodies to the virus
in the serum of the patient; demonstrate that proviral
DNA could be found integrated in the DNA of the cells
from which the virus was isolated; and provide evidence
that this was not a one-time affair by showing serologicalRetrovirology 2009, 6:40 http://www.retrovirology.com/content/6/1/40
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evidence of specific antibodies not only in the patient but
in some others as well.
Most or all these results were obtained by the time Gallo
submitted the first paper to PNAS allowing it to quickly be
followed with several other reports[12]. The paper on the
first isolation of HTLV-I [2] was submitted (communi-
cated) for publication in PNAS on August 4th 1980 and
appeared in the December issue of the same year. The sec-
ond paper from Gallo and his group (especially Bernard J.
Poiesz, another post doctorial fellow) on the isolation of
HTLV-I now from fresh cultured cells from a patient with
Sezary T-cell leukemia was submitted to Nature on May
1st 1981 and appeared in the November 19th issue of that
journal[13]. In the February 19th 1982 issue of Science
(submitted October 6th 1981) Gallo's group [14]
reported that five of six tested ATL patients in Japan had
antibodies to HTLV-I (only HTLV at the time).
On the 26th of June 1981 (six months after the Poiesz et
al. paper from Gallo's group was published) Hinuma et al.
submitted (communicated) a paper to PNAS showing
antibodies against an antigen in a T-cell line, MT-1 from a
patient with adult T-cell leukemia (ATL), in all 44 patients
with ATL examined and in 32 of 40 patients with malig-
nant T-cell lymphomas using indirect immunofluores-
cence[15]. The antibodies were also detected in 26% of
the healthy adults examined from ATL-endemic areas but
in only a few of those examined from ATL-non-endemic
areas. Extra-cellular type C virus particles were detected in
pelleted cells of the MT-1 T-cell line. Hinuma called this
virus adult T-cell leukemia virus (ATLV). Characterization
of the virus as a retrovirus was published in the March
issue of PNAS, submitted (communicated) November
23rd 1981. In this paper[16] also proviral DNA was
detected in fresh peripheral lymphocytes from all of five
patients with ATL but not in those from healthy adults.
This paper was submitted more than a month later than
the Gallo paper showing antibodies to HTLV-I in Japanese
ATL patients.
On July 13th of 1981 Miyoshi et al. (Hinuma last author)
submitted a paper to Nature (published December 24th
1981) on the transmission of virus from MT-1 cells
(female) to cord blood cells of a male infant transforming
(immortalizing) the latter cells[17].
In the November 4th 1982 issue of Nature Gallo's group
together with the Japanese colleagues Nakao, Miyoshi,
Minowada, Yoshida and Ito reported that HTLV-I and
ATLV was one and the same virus[18] and decided to call
both viruses HTLV-I.
As is evident from the above Gallo was truly the first to
isolate the first known human retrovirus and to report it.
In 1982, Gallo and co-workers reported the discovery of
the second human retrovirus, HTLV-II, in a patient with
hairy cell leukemia. However, no malignancy or other dis-
ease has yet been clearly linked to the infection of this
virus.
The isolation of what is now called HIV-1 (will also be 
referred to as HIV, LAV, IDAV-1, IDAV-2, LAV-1, HTLV-III 
and ARV) and the demonstration of this virus as the cause 
of AIDS
In May of 1983 Françoise Barré-Sinoussi et al. published a
paper in Science [19] describing the isolation of a putative
new human retrovirus from the lymph gland of a patient
suffering from persistent generalized lymphadenopathy,
which is regarded as a precursor condition of AIDS. They
called this new virus LAV (later LAVBRU) for lymphaden-
opathy virus and BRU from the first three letters of the
patient's last name. Since this has been viewed as a semi-
nal paper for the discovery and characterization of HIV, I
will here describe this paper in detail.
Cells from a lymph node of patient B.R.U. was cultured
under the conditions described by Gallo[2,13], i.e. culture
medium with T-cell growth factor (TCGF or IL-2), and
were stimulated with phytohemaglutinin (PHA). They
also added antiserum to human α-interferon to neutralize
possible endogenous interferon. (The latter is not neces-
sary, and is not used by others.) After three days, the cul-
ture was continued in the same medium without PHA.
After 15 days in culture reverse transcriptase (RT) activity
was detected in the culture supernatant, using the proto-
col by Gallo[2,13]. Importantly, the ionic conditions were
the same as for isolating HTLV-I previously described by
Gallo (1 and 2; in contrast to other animal retroviruses
HTLV-I has a Mg2+-dependent and not Mn2+-dependent
reverse transcriptase). Virus production continued for 15
days and decreased thereafter, in parallel with the decline
of lymphocyte proliferation. A standard and routine pro-
cedure in clinical virology when trying to isolate a virus is
to passage the cells to fresh ones, usually when the origi-
nal cells start to die, and particularly if they do not yet
show any signs of being infected. Hence, to show virus
transmission, cells from patient B.R.U. after three days in
culture were also co-cultured with lymphocytes from a
healthy donor of the Blood Transfusion Center at the Pas-
teur Institute. Also with these co-cultures, RT could be
detected after 15 days of culture (not before) and amounts
of RT remained stable for 15 to 20 days. Transmission of
cell-free supernatants from the original culture of B.R.U.
cells was successfully obtained using 3-day-old cultures of
T lymphocytes from two umbilical cords. There is no men-
tioning of cytopathic effects in any of the cultures or that
fresh T lymphocytes from healthy donors were added to
make the virus isolation possible or to save the virus iso-Retrovirology 2009, 6:40 http://www.retrovirology.com/content/6/1/40
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late except for the virus transmission experiment
described above.
The virus isolate had a density of 1.16 (same as HTLV-I) in
a sucrose gradient. Electron micrographs of the virus from
the umbilical cord lymphocytes were reported to be of
typical C-type virus, i.e. with a spherical core (same as
HTLV-I). Of note, HIV is a lenti retrovirus having a conical
or cylindrical core structure and does not have type C virus
morphology.
Two experiments were performed to distinguish the new
isolate from HTLV-I. The first was by immunofluorescense
using serum from the patient as well as a goat anti HTLV-
I p24 (capsid protein) and mouse monoclonal anti HTLV-
I p19 (matrix protein). The two latter anti-sera, as well as
two HTLV-I producing cell lines were from Robert C.
Gallo as acknowledged by the French group in the paper.
The sera were tested against two different cultures of nor-
mal blood lymphocytes, against the two lines of HTLV-I
producing cells, and against virus producing cells from the
co-culture of T lymphocytes of patient B.R.U. and the
healthy donor and against infected cord blood lym-
phocytes. In addition cells from a lymph node from a per-
son (patient 2) who presented with multiple
adenopathies and who had been in close contact with an
AIDS case was also tested. No RT activity was detected in
the latter patient's cultured lymphocytes. The anti-HTLV-I
sera from Gallo (anti p19 and p24) reacted with the
HTLV-I producing cell lines only. Serum from patient
B.R.U. reacted with 90–100% of the HTLV-I producing
cell lines and with 90–100% of the co-cultured cells from
B.R.U and the healthy donor, as well as, the cells from
patient 2. The B.R.U. serum reacted with only 0.5 to 2% of
the infected umbilical cord lymphocytes. It is noteworthy
that B.R.U.'s serum reacted with 90–100% of the co-cul-
tured cells from B.R.U and the healthy donor since we
know that only the CD4 positive cells should be infected.
The B.R.U.'s serum also reacted with 90–100% of the
HTLV-I producing cells! If this were to be due to a possible
double infection with HIV and HTLV-I again only CD4
positive cells should be positive. More likely something
unrelated to either HIV or HTLV-I was detected by the
B.R.U. serum, in my opinion most probably mycoplasma,
a common contaminant in cell culture. The 0.5 to 2% pos-
itive infected umbilical cord lymphocytes may indicate
retrovirus-infected cells. However, the lack of reactivity
with the p19 and p24 sera with these cells is not a proof
that the B.R.U. virus was not HTLV-I. The few percentages
of possibly positive cells could simply have been missed
with the specific antibodies but detected with the patient's
sera containing antibodies to all viral proteins. The paper
does not present any photos of the fluorescent cells.
The other experiment performed to distinguish the new
virus from HTLV-I was immunoprecipitation of lysates of
infected cord lymphocytes, as well as, virus released from
the infected cells with the same sera used for immunoflu-
orescense and in addition serum from patient 2. Serum
from B.R.U. and patient 2 (whose lymphocytes were RT
negative) precipitated a protein of the apparent size of
25,000 from extracts of the infected cord lymphocytes and
from the supernatants of these cells. Serum from a healthy
donor did not precipitate this protein, nor did the anti
HTLV-I p19 or p24 sera. The sera from B.R.U. and patient
2 did not precipitate the p25 protein from an extract of
one of the HTLV-I producing cell lines. However, neither
did the goat anti HTLV-I serum from what I can determine
from the figure presented! Thus, there is no positive con-
trol indicating that they indeed had an HTLV antigen to
precipitate. If the goat antiserum indeed precipitated a
p24 protein from the HTLV-I producing cell extract, the
band of p24 precipitated was extremely week, indicating
that the serum was not very good at precipitating HTLV-I
p24, at least not in the hands of Barré-Sinoussi and cow-
orkers. The HTLV-I producing cells were all infected as
opposed to only 0.5 to 2% of the cord blood cells. So, if
the cord blood cells were infected with HTLV-I and not a
new virus, the goat antiserum would still have had a hard
time precipitating any protein! An appropriate control
would have been a serum from a HTLV-I infected individ-
ual. The size of the protein they precipitated is in fact
24,000, the same as that of HTLV-I. The core protein of
both HIV and HTLV-I is 24,000.
In reality, in my view there is no evidence whatsoever in
this paper that a new human retrovirus has been isolated!
With the data presented, the virus they isolated could well
have been HTLV-I or in particular HTLV-II. The paper was
obviously written in haste, as acknowledged by Montag-
nier[20], and contains numerous errors and omissions in
the figures legends.
After having a first manuscript being rejected by Nature,
Gallo suggested to Montagnier to send it to Science and
even strongly endorsed the paper to the journal (the book
of Nikolas Kontaratos shows a facsimile of Gallo's letter to
the editor of Science[21]).
A more thorough description of the French isolate LAV
from patient BRU and two new retrovirus isolates from
two patients with AIDS was given at a Cold Spring Harbor
meeting held in September of 1983. A proceedings, how-
ever not peer reviewed, from the meeting was published
not until September of 1984[22]. The oral presentation by
Luc Montagnier at this meeting is to my mind the first
report on a new third human retrovirus, in that electron
micrographs on the isolate LAV from patient BRU clearly
showed virus with conical cores. A selective tropism ofRetrovirology 2009, 6:40 http://www.retrovirology.com/content/6/1/40
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LAV to CD4 positive T-cells (as is the case for HTLV-I) was
also demonstrated.
The first publication in a peer reviewed journal indicating
the isolation of a new retrovirus, distinct from HTLV-I and
HTLV-II, isolated from two siblings with hemophilia B of
whom one with AIDS, appeared in Lancet in April of 1984
and was written by the French group[23]. Again the
immunological and molecular characterization of the iso-
lated virus does not convincingly separate the isolated
virus from HTLV-I. However, an electron micrograph
clearly depicts a virus with a lenti retrovirus type morphol-
ogy having a cylindrical or conical core, distinctly differ-
ent from the larger spherical core of HTLV-I, and HTLV-II.
The paper, however, fails to conclusively link the new
virus as the causative agent of AIDS.
In conclusion, by April of 1984 the Pasteur group headed
by Luc Montagnier had reported on a new human T-lym-
photropic retrovirus distinct from HTLV-I and HTLV-II as
judged by morphology and which was present in a few
patients with AIDS and lymphadenopathy, as well as, in
people at risk of acquiring AIDS. The virus infected CD4-
positive T-lymphocytes, the very cells affected in AIDS.
Although clearly associated with AIDS, they had not yet
shown that the new virus was an etiological agent, and the
only one at that, of this new disease.
On May 4th of 1984 four papers by Robert C. Gallo's group
were published in Science describing a new human retro-
virus virus as the probable cause of AIDS. All four papers
were submitted the 30th of March 1984. One paper[24]
describes the isolation of the new virus from cultured lym-
phocytes obtained from 48 different individuals. The cul-
turing technique was what had previously been described
by Gallo and which Montagnier's group also used. The
new cytopathic (large multinucleated cells) virus isolates
were collectively designated HTLV-III and was character-
ized by having a Mg2+-dependent reverse transcriptase,
being transmittable by co-cultivation of T cells with irradi-
ated donor cells or with cell free fluids, having distinct
morphology by electron microscopy, and by expressing
specific viral antigens (indirect immune fluorescence)
using a serum obtained from a patient with pre-AIDS
(described in an adjoining papers 25 and 26; this serum
did not react with cells infected with HTLV-I or HTLV-II),
as well as, antisera prepared against purified, whole dis-
rupted HTLV-III. The 48 HTLV-III isolates were obtained
from 18 of 21 tested patients with unexplained lymphad-
enopathy and leukopenia, with an inverted T4/T8 lym-
phocyte ratio (designated pre-AIDS), 3 of 4 clinically
normal mothers of juvenile AIDS patients, 3 of 8 juvenile
AIDS patients, 13 of 43 adult AIDS patients with Kaposis
sarcoma, 10 of 21 adults AIDS patients with opportunistic
infections, and 1 of 22 clinically normal homosexual
donors. Importantly, this homosexual donor, from whom
HTLV-III was isolated, developed AIDS six month after the
virus isolations were performed. This means that these
isolations were performed not later than September of
1983. HTLV-III could not be isolated from any of 115 clin-
ically normal heterosexual donors.
In a second accompanying paper [25] antibody reactivity
to HTLV-III antigens in patients with pre-AIDS and AIDS
was determined by an enzyme-linked immunosorbent
assay (ELISA) as well as a Western electrophoretic blotting
technique using a lysate of sucrose gradient purified
HTLV-III from a cell line continuously producing HTLV-
III. [26] as antigen. The number of sera that gave positive
scores in the ELISA were: 43 of 49 (88%) of patients with
AIDS (two of whom had developed AIDS after blood
transfusion), 11 of 14 patients with pre-AIDS, 3 of 5 intra-
venous drug users (of which one positive was also homo-
sexual), 6 of 17 homosexual men. It is noted in the paper
that these homosexual men had been seeking medical
assistance; they probably were not representative of the
homosexual population. Out of 186 controls only one
scored positive in the ELISA (1 of the 164 normal sub-
jects). The controls also included 3 patients with hepatitis
B virus infection, 1 with rheumatoid arthritis, 6 with sys-
temic lupus erythematosus, 4 with acute mononucleosis,
and 8 patients with lymphatic leukemias. Of the latter
some were positive for HTLV-I. None of these 22 control
patients scored positive in the ELISA or Western blot. Of
note, in Western blot the antigen most prominently and
commonly detected among all of the sera from AIDS
patients had a molecular weight of 41,000 (now desig-
nated gp41). It was presumed that this is a virus envelope
protein (which later turned out to be correct). Others,
including myself, have later confirmed that gp41 is
extremely reactive in ELISA of sera from HIV infected indi-
viduals. In fact we have found that an ELISA having as
only antigen a peptide with the amino acids GKLICT, rep-
resenting an epitope of gp41, reacts positively with the
majority of sera from HIV infected individuals.
The French group did not detect gp41 in their immune
precipitation studies using purified LAV. Their inability to
detect this protein in their ELISA or immune precipitation
experiments is probably the main reason that their posi-
tive scores with AIDS and pre-AIDS sera were so low. HIV
is an enveloped virus and hence fragile. Most certainly
they had lost the virus envelope in their purification of the
virus.
Taken together, these two papers from Gallo's group for
the first time convincingly demonstrated that AIDS was
caused by a new human retrovirus distinct from HTLV-I
and HTLV-II. It also provided with a blood test (ELISA) by
which blood donors could be screened and a confirma-Retrovirology 2009, 6:40 http://www.retrovirology.com/content/6/1/40
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tion assay (Western blot) for those who tested positive in
the ELISA. The authors speculate that the virus they found
could well be the same virus that was previously detected
by the French group, but direct comparisons had not yet
been performed.
A third paper. [26] describes the establishment of cell
lines continuously producing HTLV-III. A total of 51 sin-
gle cell clones (designated H1 to H51) were obtained
from a neoplastic aneuploid T-cell line (HUT-78). The
clones were tested for susceptibility to concentrates of
HTLV-III. All clones were susceptible and permissive for
the virus, but virus yields and cell proliferation varied con-
siderably. The best clones (H4 and H9) were used for the
long-term propagation of HTLV-III from patients with
AIDS and pre-AIDS. Five different isolates using the H4 or
H9 clones are presented. Four were obtained by co-culti-
vating the patients T-cells with the H4 cells and one by
infecting H9 cells with a cell free concentrated culture
fluid harvested from T-cell cultures from a patient (W.T.)
who had lymphadenopathy. One was from an AIDS
patient from Haiti (R.F.) and four were from the US. In the
paper they also report that some of the 48 isolates
described in the accompanying paper[24] also could be
propagated in the H4 and H9 clones. The importance of
this paper is that for the first time it was shown that one
could propagate HIV in large quantities as a source for
antigen in a blood test, as well as, for in depth characteri-
zation of the virus. It was this paper, and the patent which
was based upon it, that later caused the controversy
between the NIH and the Pasteur Institute. It turned out
that the HTLV-III producing H9 clone selected for the
blood test was in fact a pick-up of a French HIV isolate
sent to Gallo in September of 1983. This will be discussed
later.
The fourth of the Gallo Science papers [27] describes a
first attempt to serologically characterize HTLV-III using
Western blot and sera from AIDS and pre-AIDS patients.
The paper describes for the first time a virus protein of
approximately 130,000 (in fact it is 120,000 and now des-
ignated gp120). Also a protein of 55,000 (p55) is
described and correctly concluded to be a precursor pro-
tein for the capsid protein p24.
Lastly, a photomontage of electron micrographs of HTLV-
I, HTLV-II, and HTLV-III with budding virus particles,
immature virus particles and mature virus particles is
shown. Although the budding and immature virus parti-
cles are very similar for all three viruses, the mature HTLV-
III viruses are distinctive from those of HTLV-I and HTLV-
II.
Three more papers on antibody reactivity to LAV/HTLV-III
in patients with AIDS or pre-AIDS were published in the
summer of 1984. June 9th, Montagnier's group[28] pub-
lished an ELISA based on purified virus particles. The pre-
sented results were: 18/48 (37.5%) of AIDS patients, 38/
51 (74.5%) of pre-AIDS patients and 8/44 (18%) of
homosexual men without pre-AIDS, but only one of 100
unselected blood donors were positive. In a note added in
proof they claim that by modifying their assay now 75%
of AIDS patients and 90% of pre-AIDS patients scored
positive. In the Lancet issue of June 30th Gallo's group[29]
publish their second report (the first being the one in Sci-
ence above) on ELISA and Western blot confirmatory
assay in a double-blind seroepidemiological study. The
composite result of the two assays gave: 34 of 34 AIDS
patients were positive (100%), 16 of 19 (84%) of lym-
phadenopathy (pre-AIDS), 3 of 14 (21%) at risk for AIDS,
and none of 14 controls were positive. Lastly, Kalyanara-
man et al. [30] published a paper the 20th of July in Sci-
ence submitted May 4th  1984. This paper was from
Donald Francis group at the Center for Disease Control,
Atlanta, in collaboration with Montagnier's group at Pas-
teur. The assay they used was based on immuno-precipi-
tation. The positive scores were: 51 of 125 (41%) of AIDS
patients; 81 of 113 pre-AIDS patients, 0 of CDC workers,
and 0 of 189 random blood donors. Of 100 blood sam-
ples collected in 1978 from homosexual men in San Fran-
cisco, only one was positive as opposed to 12 of 50 such
sera collected in 1984.
In the July 6th issue of Science (submitted April 6th 1984),
Donald Francis' group in collaboration with Montagnier's
group reported on the isolation of a retrovirus from a
blood donor-recipient pair with AIDS [31]. In an elegant
experiment, using a competition radioimmunoassay they
clearly show that the viruses they isolated were closely
related to LAV but not to HTLV-I or HTLV-II. This is the
first paper to show transmission of HIV-1 from one
patient to another. This is also the first time, beside the
electron microscopic pictures of LAV, Montagnier con-
vincingly shows that LAV is antigenic distinct from HTLV-
I.
On August 24th 1984 Jay Levy in San Francisco[32] pub-
lished a paper in Science (submitted May 31st) reporting
that using the Gallo protocol they had isolated a retrovirus
with lenti retrovirus type morphology designated ARV for
AIDS associated retrovirus in 22 of 45 patients with AIDS.
Positive virus cultures were also received from 5 of 10
patients with lymphadenopathy (pre-AIDS), 3 of 14 male
sex partners of AIDS patients, 2 of 9 clinical healthy
homosexual men, and 1 of 23 clinically healthy hetero-
sexual men. When tested in immune fluorescence with
slides containing acetone fixed cells infected with ARV,
HTLV-I or LAV, 78/86 (91%) of AIDS patient's sera were
positive to ARV infected cells, 22 of 40 (55%) to LAV, and
8 of 60 (13%) to HTLV-I. None of 56 controls reacted toRetrovirology 2009, 6:40 http://www.retrovirology.com/content/6/1/40
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any of the virus-infected cells. The fixed ARV infected cells
were from a cell line (HUT-78) successfully established to
continuously produce ARV.
The LAV/HTLV-IIIB contamination story and the patent 
feud between the Pasteur Institute and NIH
Right before the first public announcement by Barré-
Sinoussi at a conference at Cold Spring Harbour in May of
1983 of the Pasteur group's findings, the Pasteur Institute
filed a patent for the virus they had isolated. Before going
public with the four Science papers, the NIH filed for a
patent for the blood test described in one of the papers to
be published in May of 1984. The United States patent
office quickly allowed the American patent, shortly to be
followed by allowances from European patent offices, and
a number of American companies started to produce and
sell blood tests. The approval of the Pasteur patent was
delayed, principally because the French had not reduced
their patent to practice, i.e. showed that they had a work-
ing blood test in the patent application. This led to a pat-
ent feud between the NIH and the Pasteur Institute
starting in August of 1985. To solve this feud, the govern-
ments of both countries had to become involved. The pat-
ent fight came to an end on March 31st, 1987, when
President Ronald Reagan and French Prime Minister
Jacques Chirac signed an agreement to settle the argu-
ments. The financial outcome of the agreement, however,
did not turn out to the satisfaction of the French, and
when it became clear that the US patented blood test was
based on a laboratory contamination of a French virus the
deal was re-negotiated in 1994. It should be stated right
away that neither of the scientists at the time stood to gain
from respective patent.
The ground for the feud was the following. Montagnier
sent his first isolate LAVBRU to Gallo in July of 1983. In
May of 1984 Gallo's coworker Sarngadharan brings one of
Gallo's five HIV strains (HTLV-IIIB) that grew well in a
continuous cell line to Montagniers laboratory in Paris. In
July of 1984 Montagnier sends Gallo a second sample of
LAVBRU since Gallo had complained that the first didn't
grew well at NIH. Gallo then found and reported[33] that
HIV was extremely variable; every isolated strain was dif-
ferent from the other also when obtained from the same
individual but at different times. However, the two strains
LAVBRU (received in July of 1984) and HTLV-IIIB isolated
on either side of the Atlantic Ocean where strikingly sim-
ilar. Gallo's reaction to this was that Montagnier must
have contaminated his cultures with the American isolate,
i.e. that the Pasteur group had had a so-called "pick-up" of
HTLV-IIIB into his poorly replicating LAVBRU. Gallo gave
Montagnier a call, but the latter denied that this could
have happened in his laboratory. Since the LAVBRU
obtained by other laboratories, before HTLV-IIIB had been
introduced to the Pasteur laboratory, had a genome more
or less identical to the French isolate, it was concluded
that the contamination must have happened in Gallo's
laboratory. Gallo found this very strange, since LAVBRU
replicated very poorly and could not be transferred to a
continuously producing cell line like they had achieved
with HTLV-IIIB. On Sunday, November 19th, 1989, the
Chicago Tribune published a 16 pages account by journal-
ist John Crewdson of the discovery of HIV. The article con-
cludes that HTLV-IIIB is LAVBRU. Crewdson implied in not
so subtle words that Gallo had stolen the virus from the
French. This started three separate investigations for scien-
tific misconduct by Popovic and Gallo that didn't end
until November of 1993.
The explanation came in 1992. Sequencing the original
isolate LAVBRU received in NIH in 1983, Gallo found that
it was different from the LAVBRU received in July of 1984.
The original LAVBRU was as expected of the slowly replicat-
ing CCR5 co-receptor using genotype whereas LAVBRU
from 1984 was of the rapidly replicating CXCR4 using
genotype. In fact the 1984 LAVBRU was identical to LAVLAI.
Thus, the contamination had originally occurred in the
Pasteur laboratory. According to Montagnier at least six
other laboratories received the LAI sample (under the
name BRU) from his group and experienced the same
contamination. [34]. Montagnier speculates that this was
due to Mycoplasma pirum contamination of the cultures
infected with LAVLAI. In his review "A history of HIV dis-
covery" in Science. [34] Montagnier writes: "This physical
association makes a fraction of the LAI virus highly infec-
tious, and, in fact, this fraction can be neutralized with
antibodies against M. pirum. As mycoplasmas are com-
mon contaminents of cultured cells, an infectious pseudo-
type virus (LAI associated with M. pirum) may have caused
several contaminations between 1983 and 1984 in differ-
ent laboratories".
In Gallo's laboratory LAVBRU had contaminated a pool of
viruses from different AIDS patients. Pooling viruses was
the idea of Mika Popovic in order to get the "survival of
the fittest" to grow out in the continuous cell line H9, a
subclone of the HUT-78 cell line. The virus that grew best
was named IIIB because it was from the B-pool of two
pools in culture.
Many probably thought that the finding that a contamina-
tion had taken place already in the Pasteur laboratory was
"convenient" for Gallo. However, to "steal" the French
virus Gallo must have had a motive. One would have
been that they couldn't culture any virus from AIDS
patients and were becoming desperate. However, Gallo
had already recognized that the French group was first to
isolate a new retrovirus from AIDS patients. More so he
endorsed the publication of the first Pasteur paper, which
(although in my opinion erroneously) claimed so. Sec-Retrovirology 2009, 6:40 http://www.retrovirology.com/content/6/1/40
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ondly, Gallo's group already had 48 (sic!) isolates many
growing short term in their laboratory of which five were
growing in continuous cell lines[24,26]. Gallo's misfor-
tune was that he decided to choose the IIIB for the blood
test and for further characterization of the virus. Had he
chosen a Haitian strain, which he also had growing long
term in the laboratory at the time, we now know that he
would have chosen a virus, which was as much of a proto-
type strain for HIV-1.
It has been questioned whether Gallo indeed had all those
isolates. Considering that Gallo published this and that he
and his laboratory was scrutinized for almost five years by
three different investigations, had Gallo not had those iso-
lates he would for sure have been found guilty of scientific
misconduct and expelled from the NIH. Going through
13 foot high pile of Gallo's lab records including labora-
tory note-books, some 10,000 man hours of interviews
with laboratory personal and other witnesses, all the
Office of Research Integrity (ORI; a non-scientist office of
government consisting of lawyers and administrators)
could come up with in criticism was for Mika Popovic that
he wrote "ND" in two occasions in one published table
(in paper 25), and found him therefore guilty of scientific
misconduct. The table legend didn't define "ND" and it
was the ORI's understanding that "ND" meant, "not
done" and that Popovic indeed had performed the exper-
iment. However, Popovic insisted that by "ND" in his
notebook he meant, "not determinable". The paper was
written while Popovic was on holiday back in Czechoslo-
vakia. Following Popovic's appeal to the Research Integ-
rity Adjudications Panel the decision of ORI's was
reversed. Gallo was temporarily criticized by the ORI for
having written a sentence in the discussion of the same
paper that LAVBRU had not yet been growing well enough
to make possible comparisons with IIIB when in fact a
technician of Popovic's had done so. These charges were
later dropped by the ORI. In its decision on the Popovic
case the Departmental Appeals Board's Research Integrity
Adjudications Panel writes: "One might anticipate that
from all this evidence, after all the sound and fury, there
would be at last a residue of palpable wrongdoing. This is
not the case". It is safe to say that whatever Gallo claimed
he had, he had.
Conclusion
There is no doubt that Luc Montagnier's group at the Pas-
teur Institute in Paris was the first to isolate the causative
agent of AIDS. Montagnier, however, got the idea to try to
isolate a retrovirus indirectly from Robert Gallo and
Myron Essex. The protocols he used for virus isolation and
RT detection were developed by Robert Gallo and the rea-
gents he used to discriminate the new virus from HTLV-I
and HTLV-II were obtained from Robert Gallo. Moreover,
it is well known that Francoise Barré-Sinoussi had spent
time in Robert Gallo's laboratory to learn to culture lym-
phocytes. Robert Gallo was the first to convincingly show
that the new human retrovirus (HIV) was the causative
agent of AIDS, and the only one at that. He also was also
the first to provide a blood test to screen blood donors for
HIV infection. The rapid implementation of the latter in
the US and Europe probably saved hundreds of thousands
of lives.
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